Q1 2022

Filed May 16, 2022 · 10-Q · 46 days after period end · 0001437749-22-012652

Q1 2022 · 10-Q

Revenue

$965.00K

+69.0% vs Q1 2021

Net Income

-$1.54M

N/M vs Q1 2021

EPS, diluted—

Gross Profit$521,000+124.6%

Operating Income-$1,710,000N/M

Same quarter

Metric	Q1 2022	Q1 2021	Q1 2020	Q1 2019
Revenue	$965.00K	$571.00K	$439.00K	$364.00K
Net Income	-$1.54M	-$1.88M	-$2.62M	-$2.75M
EPS Diluted	—	-$0.01	-$0.01	-$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR